Laboratory Research Collaboration
Neurogenic licensed the schizophrenia immunoassay technology from the Weizmann Institute of Science, Rehovot, Israel. Through a long-standing collaboration with the laboratory of Prof. Meir Shinitzky, a working prototype of the assay was developed and clinically tested in collaboration with researchers from the Department of Psychiatry, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, the Beer Yaakov-Ness-Ziona Mental Health Center, Ness Ziona, the Geha Mental Health Center, Petach Tikva, and the Laboratory of Biological Psychiatry, Felsenstein Medical Research Center, Beilinson Campus, Rabin Medical Center, Petah Tikva, Israel.
In March, 2017, Neurogenic moved into its new, state-of-the-art facility in the Weizmann Science Park, Ness Tziona, a short distance from the Weizmann Institute and the company's main clinical collaborator, the Beer Yaakov-Ness-Ziona Mental Health Center. A successful technology transfer process was completed by Weizmann and Neurogenic researchers in June, 2017. New researchers have joined the development team which is focusing on the optimization of the commercial immunoassay format. Wide-scale clinical testing and validation are currently being planned.